IO Biotech, Inc. (IOBT)
NASDAQ (NGS) NASDAQ (NGS) Primary OTC PINK 
Here's Why IO Biotech, Inc. (IOBT) Looks Ripe for Bottom Fishing
IO Biotech, Inc. (IOBT) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
IO Biotech, Inc. (IOBT) Upgraded to Buy: Here's Why
IO Biotech, Inc. (IOBT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
IO Biotech: A Buying Opportunity Following Phase 3 Readout In Melanoma
IO Biotech's phase 3 melanoma trial showed a strong PFS benefit, especially in true 1st-line and PD1-negative patients, despite narrowly missing statistical significance. I believe the FDA should accept a submission based on these compelling, double-blind, randomized trial results, which show consistent benefits across subgroups. Key risks include potential FDA rejection, a dilutive cash raise, and limited US patient enrollment, but upcoming catalysts could strengthen IOBT's position.
IO Biotech, Inc. (IOBT) Just Flashed Golden Cross Signal: Do You Buy?
After reaching an important support level, IO Biotech, Inc. (IOBT) could be a good stock pick from a technical perspective. IOBT recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.
